Regeneron Pharmaceuticals Inc. Watch

from S-3ASR 2 pages Fully Paid and Non-Assessable Shares of Common Stock, Par Value $.001 Per Share, Of

from 8-K 28 pages Regeneron Pharmaceuticals, Inc., as Issuer and U.S. Bank National Association, as Trustee First Supplemental Indenture Dated as of August 12, 2020

from 8-K 53 pages Regeneron Pharmaceuticals, Inc., Issuer and U.S. Bank National Association, Trustee Indenture Dated as of August 12, 2020 Debt Securities

from 10-K 2 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

from S-3ASR 41 pages Regeneron Pharmaceuticals, Inc., Issuer and U.S. Bank National Association, Trustee Indenture Dated as of , 2013 Debt Securities

from 8-K 17 pages No Affiliate (As Defined in Rule 144 Under the Securities Act) of Regeneron Pharmaceuticals, Inc. (The “Company”) or Person That Has Been an Affiliate (As Defined in Rule 144 Under the Securities Act) of the Company During the Three Immediately Preceding Months May Purchase or Otherwise Acquire This Note or a Beneficial Interest Herein. This Is a Global Note Within the Meaning of the Indenture Hereinafter Referred to and Is Registered in the Name of the Depositary or a Nominee of the Depositary, Which May Be Treated by the Company, the Trustee and Any Agent Thereof as Owner and Holder of This Security for All Purposes

from 8-K 105 pages Regeneron Pharmaceuticals, Inc. 1.875% Convertible Senior Notes Due 2016 Indenture Dated as of October 21, 2011 Wells Fargo Bank, National Association Trustee

from S-3ASR 46 pages Regeneron Pharmaceuticals, Inc., Issuer and [•], Trustee Indenture Dated as of , 2010 Debt Securities

from 10-Q 2 pages Please Print or Typewrite Name and Address of Assignee

from S-3/A 1 page Form of Certificate of Shares of Common Stock

from S-3/A >50 pages Form of Indenture

from S-3 ~20 pages Registration Rights Agreement

from S-3 ~20 pages Pledge Agreement

from S-3 >50 pages Indenture or similar

from SC 13G 1 page Indenture or similar